Key Points
- CFO Jack Anders sold 20,000 shares of Revolution Medicines on June 24 at an average price of $168.33, totaling about $3.37 million. After the sale, he still owned 123,269 shares, a 13.96% reduction in his position.
- Anders had also sold 2,722 shares on June 16 for about $424,959, adding to recent insider selling activity at the company.
- Revolution Medicines’ stock was trading near its 52-week high at $182.08, while analysts remain mostly positive with an overall “Buy” consensus, though the company continues to report losses and missed earnings expectations in its latest quarter.
Revolution Medicines, Inc. (NASDAQ:RVMD - Get Free Report) CFO Jack Anders sold 20,000 shares of Revolution Medicines stock in a transaction on Wednesday, June 24th. The stock was sold at an average price of $168.33, for a total transaction of $3,366,600.00. Following the sale, the chief financial officer owned 123,269 shares in the company, valued at $20,749,870.77. This represents a 13.96% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.
Jack Anders also recently made the following trade(s):
- On Tuesday, June 16th, Jack Anders sold 2,722 shares of Revolution Medicines stock. The shares were sold at an average price of $156.12, for a total transaction of $424,958.64.
Revolution Medicines Stock Performance
NASDAQ RVMD opened at $182.08 on Friday. The stock has a market cap of $38.71 billion, a P/E ratio of -25.75 and a beta of 1.40. The company's 50-day simple moving average is $151.78 and its 200 day simple moving average is $116.68. Revolution Medicines, Inc. has a twelve month low of $34.00 and a twelve month high of $184.39. The company has a quick ratio of 6.80, a current ratio of 6.80 and a debt-to-equity ratio of 0.19.
Revolution Medicines (NASDAQ:RVMD - Get Free Report) last posted its quarterly earnings results on Wednesday, May 6th. The company reported ($2.29) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.83) by ($0.46). During the same period in the previous year, the business earned ($1.13) EPS. As a group, research analysts forecast that Revolution Medicines, Inc. will post -7.94 earnings per share for the current fiscal year.
Institutional Inflows and Outflows
Institutional investors have recently modified their holdings of the company. Global Retirement Partners LLC boosted its holdings in shares of Revolution Medicines by 1,002.8% in the 4th quarter. Global Retirement Partners LLC now owns 397 shares of the company's stock worth $32,000 after acquiring an additional 361 shares in the last quarter. Indiana Trust & Investment Management Co bought a new stake in Revolution Medicines during the 4th quarter worth approximately $32,000. Torren Management LLC bought a new stake in Revolution Medicines during the 4th quarter worth approximately $33,000. Arax Advisory Partners acquired a new stake in Revolution Medicines during the 4th quarter valued at $38,000. Finally, Darwin Wealth Management LLC acquired a new stake in Revolution Medicines during the 4th quarter valued at $40,000. Institutional investors own 94.34% of the company's stock.
Wall Street Analysts Forecast Growth
RVMD has been the subject of several analyst reports. Weiss Ratings restated a "sell (d-)" rating on shares of Revolution Medicines in a research report on Tuesday, April 21st. Guggenheim increased their price objective on Revolution Medicines to $205.00 and gave the stock a "buy" rating in a research note on Thursday, May 7th. Piper Sandler increased their price objective on Revolution Medicines to $172.00 and gave the stock an "overweight" rating in a research note on Thursday, May 7th. Sanford C. Bernstein initiated coverage on Revolution Medicines in a report on Thursday, May 21st. They set a "market perform" rating and a $151.00 price objective for the company. Finally, Royal Bank Of Canada boosted their target price on shares of Revolution Medicines from $165.00 to $182.00 and gave the company an "outperform" rating in a research note on Tuesday, June 2nd. Three investment analysts have rated the stock with a Strong Buy rating, seventeen have given a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company's stock. According to MarketBeat.com, the stock currently has an average rating of "Buy" and a consensus price target of $123.72.
Read Our Latest Stock Analysis on RVMD
Revolution Medicines Company Profile
(
Get Free Report)
Revolution Medicines is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapies to treat RAS-dependent cancers and other diseases driven by the RAS/MAPK pathway. The company's research efforts target historically “undruggable” proteins, aiming to inhibit critical nodes in cell signaling that promote tumor growth and therapeutic resistance.
The lead pipeline includes RMC-4630, a SHP2 inhibitor; RMC-6291, a selective KRAS G12C inhibitor; and RMC-6236, a pan-RAS inhibitor designed to address multiple RAS mutations.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
